About Raphael
Peer-reviewed research, preprints, company reports, public filings and historical press coverage are separated by source type so readers can see what each record does—and does not—establish.
Watch Raphael
Raphael presented live at the September 17 Life Sciences Virtual Investor Forum. Watch the organizer-published management presentation and Q&A replay. Management statements are dated and should be assessed alongside current SEC filings and scientific sources.
Watch the full investor presentation ↗View the organizer’s event record ↗Watch the company's original introduction film, preserved from the current Wix website. This video introduces Raphael's corporate story; it is not a verified RaphaWell product demonstration or an endorsement of treatment claims.
Explore the company →Additional approved interviews, research videos and announcements will appear here when the original assets, publication rights and accurate descriptions are verified. No placeholder videos are presented as released media.
Scientific literature
Links go to PubMed, DOI or publisher records. Study type and relationship to Raphael are stated explicitly; inclusion does not turn independent, preclinical or preliminary research into a commercial product claim.
Human-neutrophil experiments and a mouse arthritis model explore CBG biology. This paper is distinct from the 12-person company-sponsored study and does not establish clinical efficacy for RaphaWell.
Preclinical research in an inflammatory lung model. The publication is evidence about the reported experiments, not a clinical result or a claim about the RaphaWell commercial product.
A published scholarly review. It does not establish a clinical treatment effect or product efficacy for RaphaWell.
Preclinical research about a research preparation. It is not clinical evidence for the RaphaWell commercial product.
Ex-vivo immune-cell experiments and mouse arthritis models. This publication is separate from the 12-person company-sponsored study and does not establish product efficacy.
An independent healthy-adult study. It did not test the RaphaWell commercial product and should not be read as Raphael product evidence.
A medRxiv preprint. It is not peer reviewed, did not test the RaphaWell commercial product, and must be interpreted using the methods and limitations in the source record.
An independent laboratory study using a human liver-chip model. The publisher record is linked directly; the article is not presented as evidence of RaphaWell product safety or efficacy.
Company record
Company-authored and company-sponsored materials are labeled separately from independent publications. The linked rheumatoid-arthritis report is a small, uncontrolled study and is not peer reviewed.
The January 4 media card on the original Wix website linked this company results sheet. It describes a small, uncontrolled proof-of-concept study and is not peer-reviewed efficacy evidence.
Raphael’s original GlobeNewswire release reporting a U.S. provisional application. It is not an issued patent or independent clinical confirmation. Legal status and later filings require counsel review.
The original company release describes a 12-person, single-group study. No control group was identified and the report did not show statistically significant blood-biomarker changes; this is company-reported preliminary research, not product efficacy.
Original dated shareholder letter from Raphael’s CEO. Historical strategy statements should not be treated as current development commitments.
B2i Digital’s organizer notice lists Raphael Pharmaceutical (OTCQB: RAPH) in the September 17 live management presentation and Q&A program. A recording is featured in the video section above.
Company-reported clinical observations, study design, source context and limitations are presented together in the rheumatoid-arthritis science record.
The report describes a 12-participant, single-group study using 0.5 mL daily for eight weeks. No control group is identified, and reported biomarker changes were not statistically significant. The preliminary observations do not establish treatment efficacy.
Company-reported filing context is maintained in the investor intellectual-property record. A provisional application is not an issued patent; current legal status requires confirmation.
Browse company announcements and scientific updates with their original dates and source labels.
Use the SEC-linked investor record for authoritative filing metadata and documents.
Original company archive
These source-linked items appeared in Raphael's original Wix Media & Publications gallery, together with its Science Data Updates library. Original source images are used where documented; other Raphael-owned visuals are labeled as editorial illustrations. Historical reporting is not a current product claim.
Original company announcement distributed through the financial news archive; research claims and limitations must be read together.
Historical reporting about a proposed research program, not a present-day treatment recommendation.
Historical reporting; the article's statements should not be read as current efficacy claims.
Historical reporting in Hebrew. Its archive context is separate from the current commercial product.
External coverage of the research center's founding and scientific context.
Historical Hebrew-language financial press coverage. The source may require a subscriber account and was not independently readable during this review.
The former Wix site linked this LinkedIn activity. The original activity identifier is retained; public access and the publisher's full text have not been independently verified.
